Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978836 | 1.00 | CCR3 (0.45) | CCR3EPHX1RXFP2MAOAMAPT | |
| SCHEMBL23769045 | 0.96 | MAOA (0.41) | CCR3EPHX1RXFP2MAOAMAPT | |
| SCHEMBL29979608 | 0.96 | MAOA (0.41) | CCR3EPHX1RXFP2MAOAMAPT | |
| SCHEMBL29978763 | 0.84 | KDM4E (0.42) | CCR3MAOAMAPTKDM4EMEN1 | |
| SCHEMBL23769410 | 0.84 | KDM4E (0.42) | CCR3MAOAMAPTKDM4EMEN1 | |
| SCHEMBL23769036 | 0.82 | MAPT (0.56) | MAPTKDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL29978853 | 0.82 | MAPT (0.56) | MAPTKDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL23769043 | 0.80 | MAPT (0.47) | MAOAMAPTKDM4EALDH1A1PYGL | |
| SCHEMBL29978517 | 0.80 | MAPT (0.47) | MAOAMAPTKDM4EALDH1A1PYGL | |
| SCHEMBL23769417 | 0.80 | NPC1 (0.50) | MAOAMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | CCR3 2844/4885EPHX1 3880/4885RXFP2 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.